# Genzyme, a Sanofi Company: Phase 3 study completed, 281 enrolled (Hemophilia)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Genzyme, a Sanofi Company |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX |
| NCT ID | NCT03754790 |
| Phase | Phase 3 |
| Status | completed |
| Conditions | Hemophilia |
| Intervention types | drug |
| Target enrollment | 281 |
| Site countries | United States, Australia, Canada, China, Denmark, France, Germany, Hungary, India, Ireland, Israel, Italy |
| Posted | 2018-11-27 |
| Planned start | 2019-01-09 |
| Event | Completed |
| Event date | 2026-09-14 |
| Last update posted | 2026-09-30 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- Phase 3: multi-site, larger budget.
- 281 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT03754790). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.